Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2009

01-02-2009 | Review

Antigen receptor signaling in the rheumatic diseases

Authors: Julie Zikherman, Arthur Weiss

Published in: Arthritis Research & Therapy | Issue 1/2009

Login to get access

Abstract

Antigen receptor signaling in lymphocytes has been clearly implicated in the pathogenesis of the rheumatic diseases. Here, we review evidence from mouse models in which B-cell and T-cell signaling machinery is perturbed as well as data from functional studies of primary human lymphocytes and recent advances in human genetics. B-cell receptor hyper-responsiveness is identified as a nearly universal characteristic of systemic lupus erythema-tosus in mice and humans. Impaired and enhanced T-cell receptor signaling are both associated with distinct inflammatory diseases in mice. Mechanisms by which these pathways contribute to disease in mouse models and patients are under active investigation.
Appendix
Available only for authorised users
Literature
1.
Abraham RT, Weiss A: Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol. 2004, 4: 301-308. 10.1038/nri1330.CrossRefPubMed
2.
Tomlinson MG, Lin J, Weiss A: Lymphocytes with a complex: adapter proteins in antigen receptor signaling. Immunol Today. 2000, 21: 584-591. 10.1016/S0167-5699(00)01716-3.CrossRefPubMed
3.
Koretzky GA, Abtahian F, Silverman MA: SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond. Nat Rev Immunol. 2006, 6: 67-78. 10.1038/nri1750.CrossRefPubMed
4.
Acuto O, Bartolo VD, Michel F: Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat Rev Immunol. 2008, 8: 699-712. 10.1038/nri2397.CrossRefPubMed
5.
Hermiston ML, Xu Z, Majeti R, Weiss A: Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. J Clin Invest. 2002, 109: 9-14.PubMedCentralCrossRefPubMed
6.
Niiro H, Clark EA: Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002, 2: 945-956. 10.1038/nri955.CrossRefPubMed
7.
8.
Buhl AM, Cambier JC: Co-receptor and accessory regulation of B-cell antigen receptor signal transduction. Immunol Rev. 1997, 160: 127-138. 10.1111/j.1600-065X.1997.tb01033.x.CrossRefPubMed
9.
Carreno BM, Collins M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 2002, 20: 29-53. 10.1146/annurev.immunol.20.091101.091806.CrossRefPubMed
10.
Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM: Lyn tyrosine kinase: accentuating the positive and the negative. Immunity. 2005, 22: 9-18.PubMed
11.
Malissen B, Malissen M: Functions of TCR and pre-TCR subunits: lessons from gene ablation. Curr Opin Immunol. 1996, 8: 383-393. 10.1016/S0952-7915(96)80129-4.CrossRefPubMed
12.
Benschop RJ, Cambier JC: B cell development: signal transduction by antigen receptors and their surrogates. Curr Opin Immunol. 1999, 11: 143-151. 10.1016/S0952-7915(99)80025-9.CrossRefPubMed
13.
Fontenot JD, Rudensky AY: A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005, 6: 331-337. 10.1038/ni1179.CrossRefPubMed
14.
Zouali M, Sarmay G: B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum. 2004, 50: 2730-2741. 10.1002/art.20487.CrossRefPubMed
15.
Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF: CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol. 1996, 157: 4371-4378.PubMed
16.
Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, Weiss A: An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell. 2000, 103: 1059-1070. 10.1016/S0092-8674(00)00209-9.CrossRefPubMed
17.
Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A: The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity. 2005, 23: 635-647. 10.1016/j.immuni.2005.11.001.CrossRefPubMed
18.
O'Keefe TL, Williams GT, Batista FD, Neuberger MS: Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med. 1999, 189: 1307-1313. 10.1084/jem.189.8.1307.PubMedCentralCrossRefPubMed
19.
Christensen SR, Shlomchik MJ: Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol. 2007, 19: 11-23. 10.1016/j.smim.2006.12.005.PubMedCentralCrossRefPubMed
20.
Tarasenko T, Dean JA, Bolland S: FcgammaRIIB as a modulator of autoimmune disease susceptibility. Autoimmunity. 2007, 40: 409-417. 10.1080/08916930701464665.CrossRefPubMed
21.
Yu CC, Tsui HW, Ngan BY, Shulman MJ, Wu GE, Tsui FW: B and T cells are not required for the viable motheaten phenotype. J Exp Med. 1996, 183: 371-380. 10.1084/jem.183.2.371.CrossRefPubMed
22.
Fukuyama H, Nimmerjahn F, Ravetch JV: The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol. 2005, 6: 99-106. 10.1038/ni1151.CrossRefPubMed
23.
Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC: Predominant autoantibody production by early human B cell precursors. Science. 2003, 301: 1374-1377. 10.1126/science.1086907.CrossRefPubMed
24.
Mohan C, Morel L, Yang P, Wakeland EK: Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J Immunol. 1997, 159: 454-465.PubMed
25.
Mohan C, Alas E, Morel L, Yang P, Wakeland EK: Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA sub-nucleosomes. J Clin Invest. 1998, 101: 1362-1372.PubMedCentralCrossRefPubMed
26.
Kumar KR, Li L, Yan M, Bhaskarabhatla M, Mobley AB, Nguyen C, Mooney JM, Schatzle JD, Wakeland EK, Mohan C: Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science. 2006, 312: 1665-1669. 10.1126/science.1125893.CrossRefPubMed
27.
Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuru S, Sakaguchi S: Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 2003, 426: 454-460. 10.1038/nature02119.CrossRefPubMed
28.
Sakaguchi S, Sakaguchi N, Yoshitomi H, Hata H, Takahashi T, Nomura T: Spontaneous development of autoimmune arthritis due to genetic anomaly of T cell signal transduction: Part 1. Semin Immunol. 2006, 18: 199-206. 10.1016/j.smim.2006.03.007.CrossRefPubMed
29.
Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, Sakihama T, Hirota K, Tanaka S, Nomura T, Miki I, Gordon S, Akira S, Nakamura T, Sakaguchi S: A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J Exp Med. 2005, 201: 949-960. 10.1084/jem.20041758.PubMedCentralCrossRefPubMed
30.
Siggs OM, Miosge LA, Yates AL, Kucharska EM, Sheahan D, Brdicka T, Weiss A, Liston A, Goodnow CC: Opposing functions of the T cell receptor kinase ZAP-70 in immunity and tolerance differentially titrate in response to nucleotide substitutions. Immunity. 2007, 27: 912-926. 10.1016/j.immuni.2007.11.013.PubMedCentralCrossRefPubMed
31.
Sommers CL, Park CS, Lee J, Feng C, Fuller CL, Grinberg A, Hildebrand JA, Lacaná E, Menon RK, Shores EW, Samelson LE, Love PE: A LAT mutation that inhibits T cell development yet induces lymphoproliferation. Science. 2002, 296: 2040-2043. 10.1126/science.1069066.CrossRefPubMed
32.
Aguado E, Richelme S, Nuñez-Cruz S, Miazek A, Mura AM, Richelme M, Guo XJ, Sainty D, He HT, Malissen B, Malissen M: Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science. 2002, 296: 2036-2040. 10.1126/science.1069057.CrossRefPubMed
33.
Liston A, Enders A, Siggs OM: Unravelling the association of partial T-cell immunodeficiency and immune dysregulation. Nat Rev Immunol. 2008, 8: 545-558. 10.1038/nri2336.CrossRefPubMed
34.
Wang Y, Kissenpfennig A, Mingueneau M, Richelme S, Perrin P, Chevrier S, Genton C, Lucas B, DiSanto JP, Acha-Orbea H, Malissen B, Malissen M: Th2 lymphoproliferative disorder of LatY136F mutant mice unfolds independently of TCR-MHC engagement and is insensitive to the action of Foxp3+ regulatory T cells. J Immunol. 2008, 180: 1565-1575.CrossRefPubMed
35.
Duan L, Reddi AL, Ghosh A, Dimri M, Band H: The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity. 2004, 21: 7-17. 10.1016/j.immuni.2004.06.012.CrossRefPubMed
36.
Naramura M, Jang IK, Kole H, Huang F, Haines D, Gu H: c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol. 2002, 3: 1192-1199. 10.1038/ni855.CrossRefPubMed
37.
Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC: B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest. 1996, 98: 2549-2557. 10.1172/JCI119073.PubMedCentralCrossRefPubMed
38.
Pugh-Bernard AE, Cambier JC: B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol. 2006, 18: 451-455. 10.1097/01.bor.0000240353.99808.5f.CrossRefPubMed
39.
Liossis SN, Ding XZ, Dennis GJ, Tsokos GC: Altered pattern of TCR/CD3-mediated proteintyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest. 1998, 101: 1448-1457. 10.1172/JCI1457.PubMedCentralCrossRefPubMed
40.
Ciszak L, Pawlak E, Kosmaczewska A, Potoczek S, Frydecka I: Alterations in the expression of signal-transducing CD3 zeta chain in T cells from patients with chronic inflammatory/autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2007, 55: 373-386. 10.1007/s00005-007-0042-6.CrossRef
41.
Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC: Altered signal transduction in SLE T cells. Rheumatology (Oxford). 2007, 46: 1525-1530. 10.1093/rheumatology/kem154.CrossRef
42.
Allen ME, Young SP, Michell RH, Bacon PA: Altered T lymphocyte signaling in rheumatoid arthritis. Eur J Immunol. 1995, 25: 1547-1554. 10.1002/eji.1830250612.CrossRefPubMed
43.
Gough SC, Walker LS, Sansom DM: CTLA4 gene polymorphism and autoimmunity. Immunol Rev. 2005, 204: 102-115. 10.1111/j.0105-2896.2005.00249.x.CrossRefPubMed
44.
Tchilian EZ, Beverley PC: Altered CD45 expression and disease. Trends Immunol. 2006, 27: 146-153. 10.1016/j.it.2006.01.001.CrossRefPubMed
45.
46.
Kozyrev SV, Abelson AK, Wojcik J, Zaghlool A, Linga Reddy MV, Sanchez E, Gunnarsson I, Svenungsson E, Sturfelt G, Jönsen A, Truedsson L, Pons-Estel BA, Witte T, D'Alfonso S, Barizzone N, Danieli MG, Gutierrez C, Suarez A, Junker P, Laustrup H, González-Escribano MF, Martin J, Abderrahim H, Alarcón-Riquelme ME: Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008, 40: 211-216. 10.1038/ng.79.CrossRefPubMed
47.
Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV, Ballinger DG, Kosoy R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantapää-Dahlqvist S, Petri M, Manzi S, Seldin MF, Rönnblom L, Syvänen AC, Criswell LA, Gregersen PK, Behrens TW: Association of Systemic Lupus Erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008, 358: 900-909. 10.1056/NEJMoa0707865.CrossRefPubMed
48.
Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A, Khalili H, Chandrasekaran A, Davies LR, Li W, Tan AK, Bonnard C, Ong RT, Thalamuthu A, Pettersson S, Liu C, Tian C, Chen WV, Carulli JP, Beckman EM, Altshuler D, Alfredsson L, Criswell LA, Amos CI, Seldin MF, Kastner DL, Klareskog L, Gregersen PK: TRAF1-C5 as a risk locus for rheumatoid arthritis – a genomewide study. N Engl J Med. 2007, 357: 1199-1209. 10.1056/NEJMoa073491.PubMedCentralCrossRefPubMed
49.
Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007, 447: 661-678. 10.1038/nature05911.CrossRef
50.
Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, Remmers E, Criswell LA, Seldin MF, Kastner DL, Amos CI, Sninsky JJ, Gregersen PK: A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004, 75: 330-337. 10.1086/422827.PubMedCentralCrossRefPubMed
51.
Gregersen PK, Lee HS, Batliwalla F, Begovich AB: PTPN22: setting thresholds for autoimmunity. Semin Immunol. 2006, 18: 214-223. 10.1016/j.smim.2006.03.009.CrossRefPubMed
52.
Cloutier JF, Veillette A: Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med. 1999, 189: 111-121. 10.1084/jem.189.1.111.PubMedCentralCrossRefPubMed
53.
Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T: Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol. 1999, 29: 3845-3854. 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U.CrossRefPubMed
54.
Cloutier JF, Veillette A: Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. EMBO J. 1996, 15: 4909-4918.PubMedCentralPubMed
55.
Vang T, Congia M, Macis MD, Musumeci L, Orrú V, Zavattari P, Nika K, Tautz L, Taskén K, Cucca F, Mustelin T, Bottini N: Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet. 2005, 37: 1317-1319. 10.1038/ng1673.CrossRefPubMed
56.
Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH: Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol. 2007, 179: 4704-4710.CrossRefPubMed
57.
Aarnisalo J, Treszl A, Svec P, Marttila J, Oling V, Simell O, Knip M, Körner A, Madacsy L, Vasarhelyi B, Ilonen J, Hermann R: Reduced CD4+ T cell activation in children with type 1 diabetes carrying the PTPN22/Lyp 620Trp variant. J Autoimmun. 2008, 31: 13-21. 10.1016/j.jaut.2008.01.001.CrossRefPubMed
58.
Lefvert AK, Zhao Y, Ramanujam R, Yu S, Pirskanen R, Hammarstrom L: PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. J Neuroimmunol. 2008, 197: 110-113. 10.1016/j.jneuroim.2008.04.004.CrossRefPubMed
59.
Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, Chan AC: PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science. 2004, 303: 685-689. 10.1126/science.1092138.CrossRefPubMed
60.
DeVoss JJ, Anderson MS: Lessons on immune tolerance from the monogenic disease APS1. Curr Opin Genet Dev. 2007, 17: 193-200. 10.1016/j.gde.2007.04.001.CrossRefPubMed
Metadata
Title
Antigen receptor signaling in the rheumatic diseases
Authors
Julie Zikherman
Arthur Weiss
Publication date
01-02-2009
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2009
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2528

Other articles of this Issue 1/2009

Arthritis Research & Therapy 1/2009 Go to the issue

Research article

Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability

Research article

The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover

Research article

Egr-1 inhibits the expression of extracellular matrix genes in chondrocytes by TNFα-induced MEK/ERK signalling

Research article

Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients

Research article

Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus

Research article

The retinoic acid binding protein CRABP2 is increased in murine models of degenerative joint disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits